tbuckley/cabot-search huggingface dataset:
The Emperor’s Itch
Authors: Mindy X. Wang, Samantha Hsieh, Eric L. Maranda, Victoria Lim, Joaquin Jimenez
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis
Authors: Francesco Ciccia, Aroldo Rizzo, Rosario Maugeri, Riccardo Alessandro, Stefania Croci, Giuliana Guggino, Alberto Cavazza, Stefania Raimondo, Alessandra Cannizzaro, Domenico Gerardo Iacopino, Carlo Salvarani, Giovanni Triolo
Journal: Annals of the Rheumatic Diseases (2016)

Objectives To investigate whether artery tertiary lymphoid organs (ATLOs) are present in giant cell arteritis (GCA) and that their formation is associated with the ectopic expression of constitutive lymphoid tissue-homing chemokines. Methods Reverse transcriptase PCR, immunohistochemical and immunofluorescence analysis were used to determine the presence of ectopic ATLOs in GCA and the expression of chemokines/chemokine receptors and cytokines involved in lymphoneogenesis in the temporal artery samples obtained from 50 patients with GCA and 30 controls. The presence of lymphatic conduits, of follicular dendritic cells (FDCs) precursors and lymphoid tissue inducer cells was also investigated. Finally, expression of CXCL13, B cell activating factor (BAFF), a proliferation-inducing ligand (APRIL) and CCL21 by isolated myofibroblasts was evaluated before and after stimulation with Toll-like receptors (TLRs) agonists and cytokines. Results ATLOs were observed in the media layer of 60% of patients with GCA in close proximity to high endothelial venules and independently by the age of patients and the presence of atherosclerosis. ATLO formation was also accompanied by the expression of CXCL13, BAFF, a proliferation-inducing ligand (APRIL), lymphotoxin (LT)-β, interleukin (IL)-17 and IL-7, the presence of FDC precursors and of lymphoid conduits. Stimulation of myofibroblasts with TLR agonists and cytokines resulted in the upregulation of BAFF and CXCL13. Conclusions ATLOs occur in the inflamed arteries of patients with GCA possibly representing the immune sites where immune responses towards unknown arterial wall-derived antigens may be organised.
Universal Genomic Testing Needed to Win the War Against Cancer
Authors: Vivek Subbiah, Razelle Kurzrock
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
98O: Characterization of tumor infiltrating lymphocytes in resectable early stage non-small cell lung cancer
Authors: S.R.R. Hall, L. Wang, T.M. Marti, R.-W. Peng, L. Froment, S. Berezowska, G. Kocher, P. Dorn, R.A. Schmid
Journal: Journal of Thoracic Oncology (2016)
Chorioamnionitis and Colonization of the Newborn Infant with Genital Mycoplasmas
Authors: Paul A. Shurin, Susan Alpert, Bernard Rosner, Shirley G. Driscoll, Yhu-Hsiung Lee, William M. McCormack, Bernardo A.G. Santamarina, Edward H. Kass
Journal: New England Journal of Medicine (1975)

To study the role of Mycoplasma hominis and T-mycoplasmas (Ureaplasma urealyticum) in chorioamnionitis, we obtained culture from 249 puerperal women and their babies. The placentas were examined histologically. Infants whose placentas showed inflammation (chorioamnionitis) had cultures positive for T-mycoplasmas more frequently (37.5 per cent) than those with normal placentas (19.0 per cent) (P = 0.021). Colonization with M. hominis was found in 16.0 per cent of the babies and was not significantly associated with chorioamnionitis. Material colonization with mycoplasmas was more frequent (73.4 per cent) and was not correlated with placental inflammation. We conclude that a substantial proportion of cases of chorioamnionitis may be caused by prenatal infection with T-mycoplasmas. The fact that these organisms are not highly virulent could explain the frequent finding of inflammed placentas from otherwise normal pregnacies. No adverse clinical effects of the placental lesions or of mycoplasmal colonization could be detected in this small study.
PTH-046 Microrna expression profiling in the plasma of patients with ulcerative colitis and colitis associated cancer
Authors: M Patel, AM Verma, I Aslam, K West, J Jameson, H Pringle, B Singh
Journal: Gut (2015)

<h3>Introduction</h3> Patients with Ulcerative Colitis (UC) are at risk of developing Colorectal Cancer, termed Colitis Associated Cancer (CAC) and are entered into a screening programme. However, colonoscopy based screening is resource intensive, invasive, can cause harm and can miss dysplastic (pre-malignant) lesions. Thus, novel, accurate biomarkers are appealing for surveillance purposes and to facilitate early treatment. This study aimed to investigate the potential of MicroRNA molecules to act as blood based biomarkers of disease progression and risk in the UC population. <h3>Method</h3> Bloods samples were collected from patients with UC, prior to surveillance colonoscopy. Total RNA was isolated from samples and processed. Applied TaqMan® human miRNA array cards (Pool A and Pool B) were used to screen for the differential expression of 754 microRNAs in the discovery cohort: active UC (n = 8), chronic UC (n = 8), primary sclerosing cholangitis (n = 8), dysplasia (n = 2), CAC (n = 4). Quantitative real-time polymerase chain reaction (qPCR) was then used to validate high priority microRNA candidates in a further, independent cohort. <h3>Results</h3> Array data was analysed using t-tests, fold changes and rank order. 28 microRNAs were chosen for further validation. Analysis of variance was used to assess differences between groups. MicroRNA 375 was shown to be significantly up-regulated in the CAC cohort (p = 0.01). Cox-regression analysis showed a Cox hazard ratio of 1.91 (p = 0.01), when based on microRNA 375 and duration of disease. <h3>Conclusion</h3> This is the first study to investigate the expression of microRNAs in the plasma of patients with UC and CAC. The study shows the up-regulation of microRNA 375 in cases of CAC. Combining several microRNAs in a panel increased the capacity of the test to distinguish between CAC and different UC activity states. This suggests that a panel of microRNAs has potential as blood based screening test. <h3>Disclosure of interest</h3> None Declared.
The Politics of Human-Embryo Research — Avoiding Ethical Gridlock
Authors: G J Annas, A Caplan, S Elias
Journal: New England Journal of Medicine (1996)

In late January 1996, President Bill Clinton signed a continuing resolution to keep the government open. Among other things, the resolution prohibits the use of federal funds for research on human embryos.1 This prohibition, which continues until September 30, the end of the current fiscal year, would become permanent if Congress reaffirms it and the President concurs.1 Compromise language to limit the prohibition to embryos created expressly for research purposes, but permitting federally funded research on “spare” embryos (those created for procreation but no longer needed) was defeated.2 A much stronger case can be made for using spare embryos in . . .
Quantitative Impairment of Primary Inflammatory Response in Patients With Cancer2
Authors: M. W. Johnson, H. I. Maibach, S. E. Salmon
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Quantitative Impairment of Primary Inflammatory Response in Patients With Cancer Get access M. W. Johnson, M. W. Johnson Search for other works by this author on: Oxford Academic PubMed Google Scholar H. I. Maibach, H. I. Maibach 4 4Address reprint requests to: Howard I. Maibach, M.D., Department of Dermatology, Unviersity of California Medical Center, San Francisco, Calif. 94122. Search for other works by this author on: Oxford Academic PubMed Google Scholar S. E. Salmon S. E. Salmon Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 3, September 1973, Pages 1075–1076, https://doi.org/10.1093/jnci/51.3.1075 Published: 01 September 1973 Article history Received: 21 May 1973 Accepted: 07 June 1973 Published: 01 September 1973
Fetal Bradycardia after Paracervical Block
Authors: Howard R. Gordon
Journal: New England Journal of Medicine (1968)

Determinations of levels of a local anesthetic (mepivacaine) during labor after paracervical block indicated a rapid absorption of the drug into the maternal blood, with peak concentrations achieved by 10 to 20 minutes, followed by prompt placental passage to the fetus. The fetal bradycardia frequently encountered with this form of anesthesia appears to be related to high concentrations of the drug in fetal blood, 12.8 to 15 μg per milliliter. Although such levels might cause neonatal depression they do not appear to be high enough to cause death of a healthy fetus. Fetal bradycardia as a result of drug toxicity should be distinguished from that due to fetal asphyxia. Paracervical block is contraindicated when placental insufficiency is anticipated.
Association and Prognostic Interaction of Podocalyxin Like-Protein with Epidermal Growth Factor Receptor Alterations in Colorectal Cancer: a Cohort Study
Authors: A.H. Larsson, S. Wangefjord, G. Emberger, M. Sundström, B. Nodin, J. Eberhard, K. Jirström
Journal: Annals of Oncology (2014)
Establishing an Anemia Clinic for Optimal Erythropoietic-Stimulating Agent Use in Hematology-Oncology Patients
Authors: Jeffrey A. Gilreath, Daniel S. Sageser, James A. Jorgenson, George M. Rodgers
Journal: Journal of the National Comprehensive Cancer Network (2008)

Erythropoietic-stimulating agent (ESA) therapy has significantly impacted the management of chemotherapy-induced anemia (CIA) by decreasing the number of red blood cell transfusions required by patients with cancer. However, managing these patients with ESA therapy has become increasingly difficult since the release of the Centers for Medicare & Medicaid Services' new National Coverage Determination document because of the disparities between this document and recommendations from expert-reviewed national clinical guidelines on the treatment of anemia. This article describes a collaborative practice agreement between pharmacists and physicians as one approach to managing CIA in hematology-oncology patients in an anemia clinic. The goal of the pharmacist-managed anemia clinic is to improve patient satisfaction and clinical outcomes associated with the treatment of CIA. This article describes the rationale for the clinic and discusses its design and implementation in managing ESA, iron, folate, and vitamin B12 therapy for CIA in hematology-oncology patients. The pharmacist's role is justified in this clinic model through increased adherence to evidence-based practice guidelines and decreased costs associated with ESA therapy.
Atopy does not modulate tonsillar size and severity of obstructive sleep apnea in children with snoring
Authors: Emmanouel Alexopoulos, Vasiliki Varlami, Georgia Malakasioti, George Haritos, Konstantinos Gourgoulianis, Athanasios Kaditis
Journal: European Respiratory Journal (2014)

Objective:  Viral respiratory infections, asthma and atopy have been implicated in the pathogenesis of obstructive sleep apnea (OSA) in childhood. However, the role of atopy is controversial. In the present study, it was hypothesized that atopy as expressed by physician-diagnosed eczema increases the risk for tonsillar hypertrophy and moderate-to-severe OSA (apnea-hypopnea index-AHI>5 episodes/h) among children with snoring referred for polysomnography.  Methods:  Data of children with snoring who were referred for a sleep study by primary care physicians were reviewed.  Results:  Data of 827 children with mean age (± standard deviation) 6.3 (± 2.5) years and median AHI (10 th -90 th  percentiles) 2.2 episodes/h (0.5-9.5 episodes/h) were analyzed. Of all 831 subjects, 134 (16.2%) had physician-diagnosed eczema, 213 (25.8%) were obese, 582 (70.4%) had tonsillar hypertrophy and 182 (22%) had moderate-to-severe OSA. Physician-diagnosed eczema was not associated with presence of tonsillar hypertrophy after adjustment for gender and age [adjusted OR = 0.95 (0.63-1.43); P=0.79]. Similarly, eczema was not associated with presence of moderate-to-severe OSA after adjustment for tonsillar hypertrophy, obesity, gender and age [adjusted OR = 1.16 (0.74-1.81); P=0.53].  Conclusions:  Among children with snoring, atopy expressed as physician-diagnosed eczema is not a risk factor for tonsillar hypertrophy and it is not associated with OSA severity.
P74 Prevalence of Specific Antibody Deficiency in Severe Asthma: Abstract P74 Table 1
Authors: S Zaidi, G Tavernier, D Ryan, RM Niven, SJ Fowler
Journal: Thorax (2015)

<h3>Introduction</h3> Patients with asthma are prone to recurrent infective exacerbations, due to viral or bacterial infections. We have previously presented retrospective data, demonstrating significantly reduced lung function in severe asthma patients with specific antibody deficiency. The prevalence and impact of specific antibody deficiency in this patient group is not known. <h3>Aim</h3> We aimed to determine the prevalence of specific antibody deficiency and its association with markers of disease severity. <h3>Methods</h3> We prospectively collected data from all new patients attending the regional severe asthma clinic. We recorded demographic details and markers of disease severity including: BTS treatment step, inhaled corticosteroid (ICS) dose, spirometry, blood and sputum eosinophil count, radiological findings such as bronchiectasis and bronchial wall thickening, exacerbations in the last year and ITU admissions. Specific antibody levels to <i>Haemophilus Influenzae</i> (Streptococcus Pneumoniae (&lt;0.35 μg/ml to at least 6 of the 12 serotypes classed as deficient) were measured. <h3>Results</h3> Data for 53 patients (39F), mean (SD) age 49.6 (15.9) years were available. Mean (SD) FEV1 was 69 (22)% predicted, ICS dose 1914 (1337) micrograms, and BMI 31.5 (8.6) kg/m<sup>2</sup>. All were at BTS step 3–5. Information on specific antibody levels was available for 43 and 45 patients for <i>H Influenzae </i>and <i>S pneumoniae </i>respectively and for both in 42 patients. Overall out of the 42 patients 35 (83%) were deficient to one or both the organisms. Of these 13 (31%) were deficient to <i>H Influenzae </i>alone, 5(12%) to <i>S pneumoniae </i>alone, and 17 (40.5%) to both. Looking at each organism separately 30 (70%) out of 43 were deficient to <i>H Influenzae</i> and 23 out of 45 (51%) were deficient to <i>S pneumoniae</i>. Of the 32 patients for whom data were available 20 (63%) had 7 or more exacerbations in the preceding year and two thirds of these had bronchial wall thickening on their CT scans. A third of patients (30%) reported at least one ITU admission. The presence of specific antibody deficiency did not correlate with any clinical or radiological findings. <h3>Conclusion</h3> Specific antibody deficiency to <i>H influenza</i> and <i>S pneumoniae</i> is remarkably common in moderate to severe asthma. Further studies are required to determine the clinical significance of this finding.
Targeting of Acute Myeloid Leukemia by Cytokine-Induced Killer Cells Redirected with a Novel CD123-Specific Chimeric Antigen Receptor.
Authors: Sarah Tettamanti, Virna Marin, Irene Pizzitola, Chiara Francesca Magnani, Greta Maria Paola Giordano Attianese, Elisabetta Cribioli, Angel Lopez, Andrea Biondi, Dominique Bonnet, Ettore Biagi
Journal: Blood (2012)
TCR signal strength controls thymic differentiation of discrete proinflammatory γδ T cell subsets
Authors: Miguel Muñoz-Ruiz, Julie C Ribot, Ana R Grosso, Natacha Gonçalves-Sousa, Ana Pamplona, Daniel J Pennington, José R Regueiro, Edgar Fernández-Malavé, Bruno Silva-Santos
Journal: Nature Immunology (2016)
An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation
Authors: JR Downing, DR Head, AM Curcio-Brint, MG Hulshof, TA Motroni, SC Raimondi, AJ Carroll, HA Drabkin, C Willman, KS Theil
Journal: Blood (1993)
ATPS-49RESULTS OF A PHASE 0 CLINICAL TRIAL IN CANINE BRAIN CANCER EVALUATING SAFETY AND ACTIVITY OF OMX-4.80P, A PROTEIN OXYGEN CARRIER IND CANDIDATE FOR TREATMENT OF GLIOBLASTOMA
Authors: Philberta Leung, Natacha Le Moan, Jen Getz, Sarah Ng, Catherine Bedard, Tina Davis, Carol Liang, Andrew Davis, Laura Serwer, Kevin Tanaka, Tim Keating, Feng Yan, Jonathan Winger, Beverly Sturges, Teri Guerrero, Peter Dickinson, Michael Kent, Stephen Cary, Ana Krtolica
Journal: Neuro-Oncology (2015)

BACKGROUND: Hypoxia in solid tumors blunts the tumor cytotoxicity of radiotherapy (RT) and is a major independent predictor of poor patient outcomes in glioblastoma (GB). To increase tumor oxygenation, Omniox has engineered a novel oxygen delivery protein, OMX-4.80P (OMX), tuned to release oxygen specifically in hypoxic tumor tissue. When given with radiotherapy, OMX significantly enhances RT efficacy in rodent tumor models. Since spontaneous canine brain cancers, including GB, share similarities with human brain cancers in terms of morphology, disease progression, and response to approved therapies, a Phase 0 clinical trial was conducted in patient dogs to assess OMX safety, PK/PD and signs of efficacy to inform human clinical strategy. METHODS: Dogs with presumed brain cancers (MRI) underwent either resection surgery with radiotherapy (Sx + RT) or stereotactic radiosurgery (SRS). In the Sx + RT group, OMX was administered once before surgery (4–48 hours pre-Sx) and twice weekly in conjunction with RT (20x2.5Gy). In the SRS group, OMX was dosed on 2 consecutive days in combination with SRS (3x8Gy). PK, CBC, blood chemistry, coagulation, and immune responses were assessed. Additionally, resected tumors were analyzed for OMX accumulation and hypoxia levels (ELISA, IHC). RESULTS: To date, 14 dogs have completed the trial (10 Sx, 5 Sx + RT, 4 SRS): Five dogs show no signs of tumor regrowth at 3 months and 2 dogs had no visible tumors at 6 months. OMX induced no dose-limiting adverse events and median T1/2 is 35h. Resected tumors show a strong correlation between OMX concentration in tumor tissue and reduced hypoxia with OMX penetrating deep into tumor tissue. CONCLUSIONS: When given in conjunction with RT regimens equivalent to human standard of care, OMX is safe and well-tolerated. Tumor tissue analysis suggests that OMX-4.80P decreases tumor hypoxia, thus supporting its further clinical development for the enhancement of radiotherapy efficacy in GB patients.
Best of<i>BJSM</i>online: highlights from the blog, podcasts, YouTube page, Google+ and more!
Authors: Karim Khan
Journal: British Journal of Sports Medicine (2016)

Can you identify the best word to capture BJSM 's offerings? What one word brings to mind: 

Of course that's in addition to BJSM content with 24 issues per year and an archive that stretches back 50 years.

Here we highlight some BJSM benefits we hope you will find easy to access (figure 1) and applicable to your clinical practice:

Facebook 

This is where you will find a wide array of resources—from infographics, to links to articles as well as pictures and videos. It is curated by @LifestyleMedic (Steffan Griffin) and feel free to make suggestions as to what would …
Cigars and Public Health
Authors: David Satcher
Journal: New England Journal of Medicine (1999)

In his historic 1964 report, Surgeon General Luther Terry concluded that “cigarette smoking is a health hazard of sufficient importance in the United States to warrant appropriate remedial action.”1 Time and again since 1964, however, we have had to address additional threats to health from other tobacco products.In the late 1960s, the major cigarette manufacturers introduced and widely promoted little cigars. Even though they were indistinguishable in appearance from standard filter cigarettes, they were exempt from the congressional ban on radio and television advertisements for cigarettes because their wrapping was made of tobacco, not paper. Consumption of little cigars . . .
Agranulocytosis Associated with Chlorpromazine Therapy
Authors: Germar Schick, Johannes Virks
Journal: New England Journal of Medicine (1956)

STUDIES concerning the clinical use of chlorpromazine (10[[gamma - dimethylaminopropyl-chlorophenothiazine) in various medical and psychiatric disorders were begun in 1951 in Europe. Since 1954 chlorpromazine has been used in increasing frequency in this country, the most common indications being mental disorders and nausea and vomiting.In the use of chlorpromazine the side effects encountered early were relatively mild in nature: drowsiness, nasal congestion, dermatitis, photosensitivity, transient hypotension, tachycardia, constipation, hypothermia, fever and Parkinsonism. Later, more troublesome side effects were described: jaundice of an obstructive type and agranulocytosis. Fortunately, the frequency of the last mentioned complications is not great.In this . . .